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Abstract
Presenilin 1 (PS1) and Presenilin 2 (PS2) are the enzymatic component of the c-secretase complex that cleaves amyloid
precursor protein (APP) to release amyloid beta (Ab) peptide. PS deficiency in mice results in neuroinflammation and
neurodegeneration in the absence of accumulated Ab. We hypothesize that PS influences neuroinflammation through its c-
secretase action in CNS innate immune cells. We exposed primary murine microglia to a pharmacological c-secretase
inhibitor which resulted in exaggerated release of TNFa and IL-6 in response to lipopolysaccharide. To determine if this
response was mediated by PS1, PS2 or both we used shRNA to knockdown each PS in a murine microglia cell line.
Knockdown of PS1 did not lead to decreased c-secretase activity while PS2 knockdown caused markedly decreased c-
secretase activity. Augmented proinflammatory cytokine release was observed after knockdown of PS2 but not PS1.
Proinflammatory stimuli increased microglial PS2 gene transcription and protein in vitro. This is the first demonstration that
PS2 regulates CNS innate immunity. Taken together, our findings suggest that PS2 is the predominant c-secretase in
microglia and modulates release of proinflammatory cytokines. We propose PS2 may participate in a negative feedback
loop regulating inflammatory behavior in microglia.
Citation: Jayadev S, Case A, Eastman AJ, Nguyen H, Pollak J, et al. (2010) Presenilin 2 Is the Predominant c-Secretase in Microglia and Modulates Cytokine
Release. PLoS ONE 5(12): e15743. doi:10.1371/journal.pone.0015743
Editor: Tsuneya Ikezu, Boston University School of Medicine, United States of America
Received August 27, 2010; Accepted November 23, 2010; Published December 29, 2010
Copyright:  2010 Jayadev et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by: National Institutes of Health (NIH) NS055652 (S.J.), American Federation for Aging Research RAG08083 (S.J.), Alzheimer
Association New Investigator Grant NIRG-06-26411 (S.J.), NIH NS056031 (R.S.M.), NIH NS062269 (G.A.G.) and a grant from the Friends of Alzheimer Disease (G.A.G.).
Human brain autopsy tissue was procured from the Alzheimer Disease Research Center NIH AG05136. Alzheimer disease patient autopsy tissue was provided by
the Alzheimer Disease Research Center, University of Washington Medical Center (P50 AG05136). The funders had no role in study design, data collection and
analysis, decision to publish or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exitst.
* E-mail: sumie@u.washington.edu
Introduction
The development of specific and effective therapies for
neurodegenerative disease will benefit from a clear understanding
of the underlying pathogenic mechanisms. Significant clues to
pathogenesis have come from the discovery of causative mutations
in familial forms of sporadic disease. Mutations in the genes
encoding presenilin 1 (PS1) and presenilin 2 (PS2) cause early-
onset familial Alzheimer disease (AD). However, despite extensive
efforts since their identification, how PS mutations cause
neurodegeneration remains unclear.
PS are intramembrane proteases that form the catalytic
component of the c-secretase complex. More than 50 putative
c-secretase substrates have been identified which regulate a variety
of cellular mechanisms including inflammation, development, and
synaptic plasticity [1]. Many PS mutations lead to decreased
generation of PS cleavage products including amyloid-beta 40
(Ab40) and the Notch intracellular domain [2,3,4,5] demonstrat-
ing that disease associated PS mutations may result in loss of
normal function. Premature truncation mutations in PS have been
reported in early onset-AD cases, supporting haploinsufficiency or
dominant negative actions as a possible pathogenic mechanism in
the development of CNS disease [6,7]. Conditional double PS
knockout mice (PScDKO) further support the hypothesis that loss
of PS function contributes to neurodegeneration. These mice
develop behavioral and neuropathological features typical for AD,
including synaptic loss, neuronal loss, and neuroinflammation
[8,9,10]. Thus, loss of PS function may be an important
contributor to the observed neuropathology.
One potential biological function that may be impacted by loss of
normal PS function is neuroinflammation. Regulation of PS during
inflammation both in vivo and in vitro has been previously reported
[11,12]. In addition, mutant PS expressing and PScDKO mice both
showabnormalneuroinflammatoryresponsessuggestingthatPSmay
function to regulate the innate immune response in the CNS [9,13].
Since those PScDKO mice lack PS1 only in forebrain neurons, the
findings may relate to the loss of PS2 in other cell types. However,
how PS influences neuroinflammation has yet to be elucidated.
Recent studies have demonstrated that PS2 is co-regulated with
NFkB and immune signaling molecules in the Toll-like receptor
(TLR) system including TLR4 and Myd88 suggesting a specific role
for PS2 in established innate inflammatory pathways [11,12].
It is widely accepted that microglia and the innate immune
system are participants in the process of neurodegeneration
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15743[14,15,16,17,18]. Microglia can be both protective and injurious,
causing neuronal injury through release of inflammatory cyto-
kines, neurotoxins and excitotoxins [19,20,21,22,23]. While the
variety of pathogen-associated molecular pattern (PAMPs) and
damage- associated molecular pattern (DAMPs) microglial acti-
vating signals continue to be characterized, it is clear that TLR
pathways mediate important signals that regulate microglia
behavior in CNS disease [16,21,24,25]. TLR activation initiates
intracellular signaling resulting in activation of transcription
factors such as AP-1 and NFkB and subsequent induction of
inflammatory cytokines [25,26]. Elevated proinflammatory cyto-
kine serum levels are associated with both the acquisition of
neurodegeneration and progression of cognitive decline [27,28].
We demonstrate here that c-secretase inhibition and specific loss
of PS2 expression results in an exaggerated cytokine response by
microglia. In microglia, PS1 and PS2 demonstrate compensatory
regulation where knockdown of one leads to upregulation of the
other, but only PS2 depletion correlated with decreased c-secretase
function. Taken together these studies support the hypothesis that
microglial PS2 functions in a manner distinct from PS1 to
downregulate proinflammatory cytokine release and thus may act
as a novel molecular modulator of microglia behavior. Abnormal
activity of PS2 either through mutation, or secondary to changes in




All animals were housed and all experiments conducted
according to the University of Washington IUCAC guidelines
and approved by University of Washington IUCAC, Protocol #
2856-01. C57Bl/6 and PS2 knockout mice, B6.129P-Psen2tm1-
Bdes/J, were purchased from Jackson Laboratories.
Microglia cell culture
Cortical tissue from postnatal day 3 or 4 (P3 or P4) wild-type or
PS2 KO mice was dissected and cut into small pieces (,1m m
3).
Tissue pieces were incubated with 0.125% trypsin at 37uC for
25 min, followed by 1 mg/ml soybean trypsin inhibitor. Cells
were dissociated by trituration in Neurobasal
TM (Gibco, Great
Island, NY) media containing 10 mM HEPES and 100 mg/ml
DNase I. Glial cells were cultured in DMEM containing 10%
horse serum and 20% L929 conditioned medium and incubated at
37u and 5% C02 for 9–14 days before microglia were detached
from the astrocyte layer via gentle tapping of flasks.
BV-2 cells were cultured in DMEM with 10% FBS. BV2 cell-
lines stably expressing PS1 or PS2 shRNA were cultured in
DMEM, 10% FBS and 5 mg/ml puromycin selection antibiotic.
Five PS1 and 5 PS2 shRNA constructs were purchased from
Sigma-Aldrich and two different shRNA sequences resulted in PS1









pressing lines were created per manufacturer’s protocol. Briefly,
5610
4 cells per 35 mm dish were infected with one of 5 PS1 or
PS2 shRNA lentiviral constructs. Twenty-four hours later,
lentiviral containing media was replaced with standard BV2
culture media for another 48 hours then replaced with 5 mg/ml
puromycin in DMEM 10% FBS. Antibiotic resistant single cells
were selected and expanded.
Western blot analysis
Primary cells were plated at 3610
5 per 35 mm dish in DMEM
with 10% horse serum overnight. BV2 and virally transduced
clonal cell line microglia were plated at 10
5 per 35 mm dish in
DMEM with 10% FBS. Cells were lysed in a protein extraction
buffer containing 50 mM Tris-HCl; 150 mM NaCl; 5 mM
EDTA, pH 7.4; 1% Na deoxycolate; 0.1% SDS; 1% Triton X-
100; 1 mM PMSF; 7 mg/ml pepstatin; 5 mg/ml aprotinin; 5 mg/
ml leupeptin; and 160 mM sodium orthovanadate, separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to PVDF membrane (Bio-Rad, Hercules CA).
Membranes were exposed to primary anti-PS2 Loop antibody
(1:1000 Calbiochem, #529594, San Diego CA), anti-PS1 CTF
loop antibody 3109 (1:1000, kind gift of Dr. Jochen Walter) and
mouse anti-bactin (1:100,000, Vector Laboraties) overnight at
4uC, then exposed to appropriate secondary antibody (1:1000 anti-
mouse or 1:1000 anti-rabbit HRP conjugated, Amersham,
Pittsburgh, PA) for 1 hour at room temperature. Proteins were
visualized with Enhanced Chemiluminescence (Pierce, Rockford,
IL). Quantification of protein was performed employing Image J
software (NIH). TACE expression was evaluated using goat anti-
TACE (1:500, Santa Cruz Biotechnology, #6416, Santa Cruz,
CA) primary antibody and donkey anti-goat (1:5000, # 2056,
Santa Cruz biotechnology, Santa Cruz, CA) secondary.
RT-PCR
Primary microglia were cultured for 24 hours, then stimulated
with 10 u/ml IFNc for 24 hours after which RNA was collected
using the Roche RNA isolation kit (Roche Diagnostics, Indiana, IN).
PSEN2 expression was measured by real-time-PCR using TaqMan
Gene Expression Assay on Demand (Applied Biosystems, Carlsbad,
CA), and analyzed with Step-One Plus software from ABI.
Cytokine measurement
Primary microglia plated at 5610
4 cells per well in poly-D-lysine
coated 96 well plates were cultured overnight followed by
stimulation with vehicle, 10 u/ml IFNc (R&D systems,Minneapolis
MN), 100 ng/ml lipopolysaccharide (LPS) (catalog # L2654, strain
026:B6 Escherichia coli, Sigma-Aldrich, St. Louis, MO) or amyloid-b
(1–42) (catalog #62-0-80, American Peptide, Sunnyvale, CA) for
24 hours. Amyloid-b 1–42 (Ab42) was reconstituted in sterile water
to a stock concentration of 350 mM and stored at 220 prior to use.
Fibrillar Ab42 was prepared as previously described [29,30]. Ab42
peptides were incubated at 37u for 3 days and used at a final
concentration of 10 mM. BV2 and shRNA expressing clones were
plated at 10
4 per well and stimulated as above. Conditioned media
was then collected and subjected to TNFa or Il-6 ELISA analysis
per manufacturer’s protocol (R&D systems). Multiplex cytokine
analysis was performed on conditioned media collected from
primary microglia and evaluated using Millipore bead array and
analyzed via Luminex 100IS system (n=3 separate experiments).
To evaluate effect of c-secretaseinhibition cells were first exposed to
the pharmacological c-secretase inhibitor, N-[(3,5-Difluoropheny-
l)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT)
for 12 hours prior addition of IFNc or LPS for 24 hours.
c-secretase activity assay
Two constructs were employed to measure c-secretase activity
in primary and cell line microglia. The APP-Gal4-VP16 and
PS2 Modulates Microglia Activation
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were subcloned into the pSL6 lentiviral shuttle vector [31].
Primary microglia were transduced with lentivirus which results in
high efficiency and without induction of microglia proinflamma-
tory activation [32]. Lentivirus was prepared through the Fred
Hutchinson lentiviral core facility (Seattle, WA, NIH Grant DK
56465). Primary and cell line microglia were plated at 10
4 cells per
well in 96 well plates. Four hours after plating, microglia were
incubated with lentiviral c-secretase assay constructs at MOI of 1-
3 for 18 hours followed by replacement with fresh culture media.
c-secretase activity was determined by luciferase activity and
measured 72 hours after initial infection. Cells were lysed and
subjected to luciferase assay as recommended by manufacturer’s
protocol (Promega, Madison, WI).
Results
c-secretase Inhibition Augments the Microglia
Proinflammatory Response
To study the role of the c-secretase complex in CNS resident
innate immune cells, we employed a pharmacological inhibitor to
block c-secretase activity in cultured primary murine microglia and
assessed microglia proinflammatory responses. We first confirmed
the presence of an intact c-secretase complex that is repressible by
the pharmacological c-secretase inhibitor, DAPT. The c-secretase
activity luciferase reporter assay has been previously described and
validated [2]. Briefly, c-secretase mediated cleavage of an APP-
Gal4VP16 fusion protein results in release of the intracellular C-
terminal fragment (analogous to the C-terminal fragment of
endogenous APP) that subsequently initiates transcription of a
luciferase gene which is downstream of a promoter containing Gal4
binding sites. Cells transduced with the reporter constructs were
exposed to DAPT or vehicle control (DMSO) for 24 hours followed
by collectionof lysate for luciferase assay. DAPT inhibits c-secretase
mediated cleavage of APP in a dose dependent manner (Fig. 1A).
In the diseased brain microglia can be stimulated by a variety of
sterile and pathogenic stimuli. We chose to stimulate primary
microglia with the canonical TLR4 stimulus, lipopolysaccharide
(LPS) to examine the interaction between TLR stimulation and c-
secretase. We incubated primary microglia with DAPT or vehicle
control(DMSO) for12 hourspriorto24 hourstimulationwithLPS
then measured the release of TNFa and IL-6, two proinflammatory
cytokines increased in neuroinflammatory and neurodegenerative
processes [33] by ELISA. Incubation with DAPT resulted in an
augmented cytokine response to LPS (Fig. 1B). The increase in
TNFa release was dose dependent and statistically significant
(p,0.01 by ANOVA) while the IL-6 response was maximal at both
doses of DAPT tested (p,0.05 by ANOVA) (Fig.1C). Treatment
withDAPT alone(intheabsenceofLPS) does notinducedetectable
cytokine release from microglia (data not shown) suggesting that c-
secretase inhibition modulates proinflammatory responses rather
than independently inducing a non-specific noxious injury. Similar
results were found using the c-secretase inhibitors L-685,458 and
Compound E. These findings suggested that c-secretase enzymatic
activity participates in the microglia proinflammatory response and
that inhibition of the c-secretase complex leads to an exaggerated
proinflammatory state in microglia.
Presenilin knockdown leads to compensatory increase of
the other Presenilin
The c-secretase complex is comprised of APH-1, nicastrin, Pen-2
and either Presenilin 1 or Presenilin 2 [34]. To further dissect the
potential mechanism by which the c-secretase complex influences
cytokine release it is necessary to determine if one or both
presenilins direct c-secretase activity in the manner described
above. Presenilins have overlapping, though distinct c-secretase
activity [35,36]. The PS1 knockout mouse is embryonic and
Figure 1. Pharmacological c-secretase inhibition enhances
proinflammatory cytokine release in primary microglia. Microg-
lia were infected with luciferase reporter c-secretase assay constructs
and exposed to vehicle control (DMSO), 1 mMo r1 0 mM of the
pharmacological c-secretase inhibitor, DAPT. A) DAPT suppresses c-
secretase activity as measured by luciferase reporter assay. Data are
means 6SEM of 3 independent experiments. Primary cultured microglia
were pre-incubated with DMSO, 1 mMo r1 0mM DAPT for 12 hours
followed by addition of 100 ng/ml LPS. (B) TNFa and (C) IL-6 release
were measured after LPS stimulation in DAPT or DMSO treated cultures.
There is a significant effect of DAPT on TNFa (**p,0.01 by ANOVA) and
IL-6 (*p,0.05 by ANOVA) release. Data represent the mean 6 SEM of 3
independent experiments.
doi:10.1371/journal.pone.0015743.g001
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isolation of PS1 knockout primary microglia to study the impact
of PS1 absence on microglia function is not practical. To
circumvent the lack of an available source of PS1 knockout primary
microglia, we used short hairpin loop RNAs (shRNA) to silence PS1
and PS2 in BV2 cells, a murine microglia cell line. Lentiviral
constructsexpressingshRNAagainstPS1and PS2and apuromycin
resistancegene wereemployed to generate stableshRNAexpressing
BV-2 clones. To control for lentivirus infection and shRNA off-
targeteffects,twounique shRNAsequencesforeachgenewereused
to generate multiple knock down clones. BV2 cells were also
infected with a lentivirus expressing a non-target shRNA (control
shRNA) against prokaryotic genes. Clonal cell lines were evaluated
for PS1 and PS2 protein expression by Western blot analysis
(Fig. 2A) and those lines expressing at least a 50% decline were
employed for subsequent functional studies. There was no
measurable effect on viability for any of the control, PS1 or PS2
knockdown cell lines.Previousworkhassuggestedthat PS1and PS2
likely exist in a co-regulated balance [37]. We indeed found PS1
knockdown clones showed increased PS2 levels compared to non-
target shRNA control lines while PS2 knockdown clones had mildly
increased levels of PS1 compared to control lines (Figs. 2A and 2C).
We found a similar compensatory increase of PS1 in the primary
PS2 knockout microglia compared to controls (Figs. 2B and 2C).
These findings demonstrate that in microglia, PS1 and PS2
expression levels are complementary to each other, such that
reduction in one PS results in a compensatory increase of the other.
PS2 is the predominant c-secretase in microglia
To determine the impact of PS knockdown on functional
enzymatic activity we measured c-secretase activity by the above
described luciferase reporter assay [2]. Surprisingly, we found a
disparate impact of specific PS knockdown on c-secretase activity.
PS1 knockdown led to dramatically increased c-secretase activity
(Fig. 3A). On the contrary, PS2 knockdown resulted in marked
decrease in cleavage of APP in spite of elevated levels of PS1
(Fig. 3B). Similarly, primary PS2 KO microglia express more PS1
than wild type microglia, but have significantly impaired c-
secretase enzymatic activity compared to control (Fig. 3C). These
novel findings indicate that while suppression of either PS leads to
a compensatory increase in expression of the alternate PS,
functional enzymatic activity of the c-secretase complex as
measured by APP cleavage in microglia is predominantly
mediated by PS2.
Deficiency of PS2 but not PS1 results in an augmented
proinflammatory response
We determined that c-secretase inhibition leads to increased
proinflammatory cytokine release in microglia and that PS2 is the
primary mediator of microglial c-secretase activity. We therefore
expected that PS2 knockdown microglia may demonstrate a
similar augmentation of proinflammatory cytokines as was
observed in response to pharmacological c-secretase inhibition.
Uninfected BV2 cells, control shRNA infected clones and PS1 and
PS2 knockdown cell lines were compared for their response to the
proinflammatory stimulus, LPS for 24 hours. As would be
expected if PS2 was the more functionally relevant PS in
microglia, PS2 knockdown cell lines secreted more TNFa and
IL-6 into conditioned media compared to control shRNA infected
BV2 clones, uninfected BV2 controls and PS1 knockdown cell
lines (Fig. 4A). To account for clone specific effects, three unique
clones expressing one of two different PS2 shRNA sequences were
Figure 2. Decreased expression of one PS results in compensatory increase of the other PS. A) PS1 C-terminus migrating at ,18 kDa and
PS2 C-terminus migrating at ,20 kDa are shown in representative western blot analyses of lysates prepared from non-target shRNA expressing
control clone (CC) and 2 BV2 clonal cell lines (1A, 1B) stably expressing PS1 shRNA and 2 BV2 clonal cell lines (2A, 2B,) stably expressing PS2 shRNA.
The panel of protein bands are taken from the same gel with irrelevant lanes removed from the figure. B) Western blot analysis of lysates prepared
from primary microglia isolated from wild-type (WT) or PS2 knockout mice (PS2 KO). Antibodies to C-termini of PS1 and PS2 show protein bands at
approximately 18 kDa and 20 kDa respectively. C) Densitometric analysis of Western blots measuring relative PS protein levels (normalized to actin)
in PS knockdown cells and in PS2 KO cells. Data represent the mean 6 SEM of 3 independent experiments (*p,0.05 by Student’s t-test).
doi:10.1371/journal.pone.0015743.g002
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clones expressing two different PS1 shRNA sequences were
averaged together for analysis of PS1 knockdown. Three
independently derived non-target control shRNA clones were
averaged together for analysis. At baseline, none of the knockdown
cell lines or uninfected BV2 cells release proinflammatory
cytokines above the limit of detection (data not shown). The effect
of PS2 knockdown on TNFa and IL-6 response release after
stimulation with LPS was significant (respectively, p,0.005 and
p,0.02 by ANOVA). In contrast, there was no significant effect of
PS1 knockdown on the TNFa response to LPS (Fig. 4A) despite
the marked reduction in PS1 protein. Interestingly, IL-6 release
was markedly reduced in PS1 knockdown cells and t-test analysis
revealed a statistically significant decrease in IL-6 in PS1
knockdown cells compared to naı ¨ve BV2 cells (p,0.02).
Since TNFa release can be induced by increased cleavage of its
membrane associated precursor, we addressed the possibility that
PS2 might regulate TNFa release by reducing the expression of
the TNFa converting enzyme (TACE). We evaluated the effect of
PS2 knockdown on TACE expressing using Western blot analysis
and observed no significant effect of PS2 knockdown on TACE
expression (Fig. S1). This suggests that PS2 does not alter TNFa
release by impacting TACE protein levels. Future studies are
aimed at measuring TACE activity in the context of PS2
knockdown and knockout.
PS2KO primary microglia also demonstrated reduced c-
secretase activity, suggesting that if c-secretase activity modulates
the pro-inflammatory response, then PS2 knockout microglia
would behave like the PS2 knockdown BV2 cell clones and DAPT
treated microglia. As predicted, PS2KO primary microglia
demonstrated increased proinflammatory cytokine release. We
observed that PS2 KO microglia released significantly increased
levels of IL-6 (Fig. 4B). To determine if IL-6 is an isolated cytokine
regulated by PS2 expression in primary cells we performed
multiplex cytokine analysis on conditioned media from wildtype
and PS2 KO microglia. We found that in addition to IL-6, IL-12
levels were increased after 24 hours LPS stimulation in PS2 KO
cells compared to wildtype. PS2KO microglia did not release
significantly increased TNFa compared to wildtype microglia as
had been observed with PS2 knockdown (Table S1). To determine
if IL-12 is also increased in PS2 KD cells we assayed IL-12 levels in
BV2 cells after LPS stimulation. We did not detect any measurable
IL-12 in BV2 cells or BV2 cell line clones. In total, PS2 deficiency
impacts multiple proinflammatory cytokines as measured in our
assay. Taken together these results further suggest that PS2 likely
regulates a general pattern of proinflammatory cytokine response.
To determine whether an AD relevant stimulus would reveal a
similar augmentation of TNFa by PS2 knockdown, we employed
10 mMA b42 to activate microglia. While LPS alone can induce
measurable cytokine release in BV2 cells, Ab42 stimulation
required priming by IFNc, an established component of classical
activation of monocytes [38,39]. Stimulation with Ab42 alone did
not induce cytokine release and incubation with IFNc did not
result in a significant difference in TNFa release between PS1
knockdown, PS2 knockdown and non-target clones (data not
shown). IFNc primed PS2 knockdown cells released significantly
higher levels of TNFa compared to primed non-target controls
(p,0.05 by ANOVA) after 24 hours stimulation with Ab42
(Fig. 4C). These data suggest that PS2 participates in the
regulation of the microglia response to LPS, a canonical TLR4
ligand as well as to Ab42 a molecule known to play a role in
neurodegenerative disease.
Proinflammatory Stimuli Increase Presenilin-2 Protein in
Cultured Microglia
Our findings suggest that PS2 acts to downregulate the
proinflammatory response in microglia as PS2 deficiency is
associated with a heightened release of proinflammatory cytokines
in response to LPS stimulation. Whether PS2 expression itself
could be regulated by proinflammatory stimuli remained un-
known. We hypothesized that PS2 participates in a negative
feedback loop in the proinflammatory response, and therefore its
expression in microglia may be modulated by LPS induced
stimulation. However, we observed that PS2 expression was not
altered in primary microglia stimulated with LPS for 24 hours
(Fig. 5A). While TLR4 signaling is an important component to the
innate immune response in CNS disease pathogenesis, it is one of
multiple inflammatory pathways mediating the microglial response
to damage and pathogen stimuli. Interferon-c (IFNc), a mononu-
clear cell regulatory cytokine proposed to play a role in
neurodegeneration, induces monocytes to adopt an activation
state characterized by release of proinflammatory cytokines and
Figure 3. c-secretase activity correlates with PS2, not PS1 protein expression. c-secretase cleavage of an APP-Gal4 construct that induces
luciferase expression was measured by determining luciferase activity in uninfected BV2 (NI), control non-target clone (CC) three PS2 shRNA
expressing BV2 cell lines (PS2 KD) and two PS1 shRNA expressing BV2 lines. A) c-secretase activity is approximately 10 fold increased in PS1 shRNA
expressing BV2 clones. Data represent the mean 6SEM of 3 independent experiments (***p,0.001 by Tukey’s post-test analysis). B) c-secretase
activity is significantly decreased in PS2 shRNA expressing BV2 clones Data represent the mean 6SEM of 3 independent experiments (*p,0.01 by
Tukey’s post-test analysis). C) c-secretase activity as measured by APP-Gal4 cleavage induction of luciferase activity in WT and PS2 KO microglia
demonstrating markedly impaired enzymatic activity in PS2KO cells. Data represent the mean 6SEM of 3 independent experiments (**p,0.005, by
Student’s t-test).
doi:10.1371/journal.pone.0015743.g003
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patients secrete higher levels of IFNc compared to controls [41]
and IFNc mediates a diverse set of inflammatory responses in
animal models of neurodegeneration and neuroinflammation
[42,43,44,45]. Therefore we evaluated the impact of IFNc
stimulation of microglia on PS2 expression. Western blot analysis
of lysates prepared from cultured primary microglia stimulated
with IFNc or control for 24 hours demonstrated statistically
significant increased PS2, but not PS1 expression (Fig. 5A–B).
Regulation of PS2 protein levels may be transcriptional or
posttranslational; therefore we measured PS2 gene expression
via real-time PCR assay. We found that IFNc induces increased
PS2 transcript, demonstrating that increased PS2 expression, at
least in part, results from induction of gene expression. These data
suggest that while PS2 appears to interact with TLR4 mediated
pathways in microglia its expression is sensitive to inflammatory
signaling by IFN-c. We hypothesize therefore that dysregulated
proinflammatory signals during neurodegeneration may concur-
Figure 4. PS2 deficiency is associated with increased proinflammatory cytokine release. A) 100 ng/ml LPS stimulation results in
significantly more TNFa and IL-6 release in three PS2 knockdown cell lines (PS2 KD) versus controls (CC). Data represent the mean 6 SEM of 3
independent experiments (**p,0.01 by Tukey’s post-test analysis). B) Cultured PS2 KO primary microglia stimulated with LPS for 24 hours released
elevated levels of IL-12 and IL-6 compared to wild-type control cells as measured by multiplex cytokine array. Data represent the mean 6 SEM of 3
independent experiments. (*p,0.05, **p,0.01 by Student’s t-test). C) Twenty-four hour stimulation with 10 mMA b42 results in significantly increased
TNFa release in PS2 KD cells versus non-target control (CC) Data represent the mean 6 SEM from 3 independent experiments (*p,0.05).
doi:10.1371/journal.pone.0015743.g004
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PS2 expression as a counter-regulatory mechanism to dampen the
proinflammatory response.
Discussion
Here we describe a novel functional role for PS2 in the
modulation of microglia behavior. Our study identifies PS2 as the
predominant c-secretase in microglia, an observation not
previously reported. Our findings also support the hypothesis that
PS2 (via its function as a c-secretase) is a molecular modulator of
microglia activation by acting as a repressor of proinflammatory
responses. Furthermore, we present evidence that PS2 expression
can be regulated by inflammatory stimuli. Therefore PS2 could
participate in a negative feedback loop whereby increased
expression of PS2 by inflammatory stimuli leads to increased
PS2 mediated c-secretase activity and subsequent dampening of
the proinflammatory response.
In the healthy CNS microglia constantly monitor their local
environment. During neurodegeneration the loss of factors that
normally repress microglia may initiate microglial ‘‘activation’’
behaviors [21]. How microglia initiate these behaviors in response
to environmental signals has not been elucidated clearly. Studies
have begun to identify both extracellular signals and signal
transduction pathways that lead to the diversity of microglial
behavior, although there are likely many regulators of microglial
function yet to be identified. We have discovered that PS2 is a
mediator of microglia proinflammatory cytokine release.
There are several potential mechanisms through which PS2 may
act in microglia. c-secretase substrates include numerous proteins
known to regulate innate immune responses including notch, low-
density lipoprotein receptor-related protein 1 (LRP1), interleukin-1
(IL-1) receptor type 1, IL-1 R2, CX3CL1, CXCL16, and the MHC
class I protein, HLA –A2 [46,47,48,49,50,51]. The notch family of
proteins are c-secretase substrates and well known transcriptional
regulators [52] that influence the innate immune system [53,54,55].
Downregulation of notch signaling in microglia leads to enhanced
levels of proinflammatory cytokines [56]. Macrophage activation
induces notch signaling through its transcriptional target, Hes-1, to
act as a negative feedback inhibitor of IL-6 transcription [55].
However, the regulation of c-secretase activity in these studies was
not the focus of investigation nor is it clear whether PS1 or PS2 was
acting as the predominant c-secretase in those cell types. These
reports are consistent with our finding that interference with c-
secretase activity either pharmacologically or through decreased
PS2 expression leads to an exaggerated proinflammatory response.
Based upon our data, it is possible that PS2 specific enzymatic
activity may be the upstream regulator of the notch pathway in
microglia. There is also evidence that PS modulates cytokine release
in immune cells independent of notch transcriptional signaling
pathways, though these pathways have not been evaluated in
microglia [57]. Thus, while notch is a candidate mediator of
microglia regulation by PS2, it is only one of several possible
substrates.
We have shown that PS2 not only modifies the innate immune
behavior of microglia but that PS2 is in turn regulated by the innate
immune response. The PS2 promoter has potential binding sites for
the transcription factors AP-1, NFkB and hypoxia-inducible factor-
1 (HIF-1), all of which are induced in response to CNS injury or
inflammation [58,59,60]. PS2 mRNA is significantly upregulated in
human neural cell lines after exposure to inflammatory cytokines
[61]. Further studies are needed to determine the mechanisms by
whichinflammatorystimuli lead to increased microglialPS2protein
expression. What role modulation of PS2 expression may have on
the proteolytic cleavage of other c-secretase substrates was not
specifically addressedinthesestudies.Futureexperimentsareaimed
at identifying additional substrates for PS2 mediated cleavage in
microglia.
In addition to demonstrating that PS2 expression in microglia is
regulated by inflammatory signals, we have discovered that PS
expression in microglial cells show compensatory regulation,
where PS1 knockdown leads to increased PS2 and vice versa.
Since germline absence of PS2 also leads to increased expression of
PS1 in primary microglia cells, the observed compensation is
unlikely to be secondary to the use of a transformed microglia cell
line or an off-target effect of shRNA. This compensation occurs in
a bi-directional fashion even though only PS2 knockdown or
knockout results in decreased c-secretase activity in microglia. Our
finding that c-secretase enzymatic activity correlates specifically
with the level of PS2 expression suggests the novel hypothesis that
PS2 is the predominant functioning c-secretase in microglia. It is
Figure 5. PS2 protein is increased in microglia activated by IFNc. A) Western blot analysis demonstrating the PS2 C-terminus migrating at
,20 kDa. Twenty-four hour stimulation with 10 u/ml IFNc induces increased levels of PS2 expression in lysates prepared from primary microglia,
while 100 ng/ml LPS does not induce PS2 expression. B) Quantitative densitometry on Western blots of lysates from 4 independent cultures shows
significantly increased induction of PS2 by IFNc. Data represent the mean 6 SEM of 4 independent experiments (*p,0.05; Student’s t-test). C)
Twenty-four hour stimulation of primary microglia with IFNc results in significantly increased PS2 mRNA. Data represent the mean 6 SEM of 3
independent experiments (** p,0.01 by Student’s t-test).
doi:10.1371/journal.pone.0015743.g005
PS2 Modulates Microglia Activation
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15743known that PS1 and PS2 have distinct expression patterns [62]
and thus we speculate that the two proteins may possess distinct
functions. It is possible that the two presenilins mediate distinct cell
type specific functions in the CNS. PS2 may play the predominant
role in regulating microglia while PS1 may have an analogous or
distinct function in other cell types.
In patients with PS1 mutations, abnormal PS1 may still impact
microglia function. Expression of mutant PS1 in a knock-in mouse
model results in accentuated inflammatory behavior in microglia
[13] and conditioned media from PS1 mutant expressing
microglia negatively impact hippocampal neurogenesis [63].
However, it is possible that proinflammatory consequences of
PS1 mutation may also be secondary to PS2 dysfunction [13]
because studies have demonstrated that mutant PS1 can interfere
with PS2 function or alter the dynamics of PS2 c-secretase
complex assembly [64,65].
We observed that the impact of PS2 deficiency on microglia
cytokine release was more dramatic than the pharmacological
inhibition of c-secretase activity. The role that PS2 c-secretase
independent mechanisms may influence microglia behavior was not
specifically addressed in this study. It is known that PS2 has non-
canonical(c-secretaseindependent)mechanismsofaction[1,66,67].
It is possible that c-secretase independent functions specific to PS2
are mediated by interactions with unique binding partners not
shared with PS1, such as the PDGF receptor [64]. PS2 deficiency
may also have secondary impacts on microglia activation by
influencing the regulation of intracellular calcium [68,69,70]. We
observed slight differences in the repertoire of upregulated cytokines
in PS2 knockdown versus PS2 KO microglia. There are multiple
biological reasons that may potentially explain these observations.
First, primary microglia are a heterogeneous population whereas
the BV2 cell line is likely to behave more uniformly in response to
stimuli. Second, because the PS2 KO cells are germline knockout
and are completely deficientin PS2compared to partial knockdown
of PS2 in cell lines, the two cell types are not complete parallels. In
aggregate, however, our data show that c-secretase inhibition and
PS2 deficiency induce an exaggerated proinflammatory response in
both cultured microglia paradigms. Future studies are needed to
investigate whether PS2 may also modulate microglia behavior via
one of its non-canonical functions.
Our findings have potentially significant implications to current
pharmacological therapeutic efforts using c-secretase inhibitors
(GSI) or modulators. We have demonstrated that c-secretase
inhibition in microglia leads to exaggerated proinflammatory
cytokine release which may be detrimental to the local CNS
environment. While these studies were not performed in vivo, they
do underscore the potential impact of GSI’s of the CNS innate
immune system. Therapeutics designed to reduce Ab deposition
through inhibition of c-secretase may paradoxically result in
further neuronal injury secondary to an exaggerated proinflam-
matory CNS milieu. Additionally, while evaluating the efficacy
and safety of c-secretase inhibition and modulation for AD and
other diseases it may be beneficial to be aware of potentially
adverse impacts on the central and systemic immune system.
In summary, we report that PS2 is the predominant c-secretase
in microglia and that PS2 deficiency leads to an exaggerated
proinflammatory microglial phenotype. Microglia have increased
PS2 protein in response to proinflammatory stimuli in vitro,
suggesting that PS2 expression may be upregulated by inflamma-
tory stimuli as part of a negative feedback loop to downregulate
microglial inflammatory processes. Further studies are underway
to identify the mechanisms by which PS2 regulates microglia
behavior as well as to determine whether PS1 and PS2 may
mediate distinct roles in other neural cells or inflammatory cells
outside the CNS. For patients with neurodegenerative diseases
exacerbated by neuroinflammation, there are currently no
available disease modifying therapies. Thus, further elucidation
of PS2 function in microglia may provide novel and specific targets
for therapeutic intervention for diseases of the CNS.
Supporting Information
Figure S1 TACE expression is not impacted by PS2
knockdown. Lysates were prepared from non-infected BV2 cells
(NI), non-target expressing control cell lines (CC), PS2 shRNA
expressing cell lines and primary microglia, were separated by
electrophoresis and transferred to PVDF membrane which was
probed for TACE protein seen at approximately 85 kDa. There
was no difference in TACE expression between BV2, non-target
cells and PS2 shRNA expressing cells.
(TIF)
Table S1 Multiplex analysis results. Multiplex analysis of
conditioned media from primary wildtype and PS2 KO microglia
stimulated with LPS for 24 hours. Values shown are the result of 3
independent experiments. Wildtype and PS2 KO microglia release
KC, Rantes and TNFa in addition to IL-6 and IL-12.
(DOCX)
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